CRISPR Therapeutics (CRSP) Tops Q4 EPS by 88c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.41), $0.88 better than the analyst estimate of ($2.29). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.12 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight